Social Behavior – Page 21

Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Collaboration, ecteribulin, Eisai, farletuzumab, Myers, portfolio, Prioritization, squibb

Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin

Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Daiichi, Deruxtecan, HER3 protein, Merck, Non-Small Cell Lung Carcinoma, patritumab, Regulatory Setback, Rejection (Psychology), Sankyo, United States Food and Drug Administration

Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)

EU Calls for Cooperation and Increased Manufacturing to Overcome GLP-1 Shortage

1 year ago talkbio0Tagged agonists, cooperation, Diabetes, EU, Glucagon-Like Peptide-1 Receptor, Manufacture, regulatory actions, shortages, Weight maintenance regimen

GLP-1 receptor agonists, EU, shortages, diabetes, weight management, manufacturing, cooperation, regulatory actions

AbbVie’s Duopa Successor in Parkinson’s Rejected Again Due to Third-Party Manufacturer Issues

1 year ago talkbio0Tagged ABBV-951, AbbVie, carbidopa, Duopa, levodopa, Manufacturer Name, Parkinson 's disease, Rejection (Psychology), subcutaneous pump device, third-party, United States Food and Drug Administration

AbbVie, Duopa, Parkinson’s disease, FDA rejection, third-party manufacturer, ABBV-951, carbidopa, levodopa, subcutaneous pump device

CDMO Leaders Unite for Turn-key Drug Production

1 year ago talkbio0Tagged CDMOs, competition, Contract Development, end-to-end services, innovation, Lung consolidation, manufacturing organizations, Market, Pharmaceutical Supply Chain, strategic partnerships, Technology

Contract Development and Manufacturing Organizations (CDMOs), pharmaceutical supply chain, advanced therapies, strategic partnerships, end-to-end services, technology innovation, market consolidation, and competitive advantage.

Taysha Gene Therapies Announces Positive Results for TSHA-102 in Rett Syndrome Trials

1 year ago talkbio0Tagged autonomic function, Communication, gene therapy, Motor Skills, Rett Syndrome, Seizures, Taysha Gene Therapies, TSHA-102

Taysha Gene Therapies, TSHA-102, Rett Syndrome, Gene Therapy, Motor Skills, Communication, Autonomic Function, Seizures

FTC Supports Rule Change to Expose Anticompetitive Drug Patent Deals

1 year ago talkbio0Tagged competition, drug patent, Legal patent, pharmaceutical companies, Prices, settlements, United States Federal Trade Commission

FTC, antitrust, drug patent deals, pharmaceutical companies, patent settlements, competition, generic drugs, price regulation

Italian Antitrust Agency Investigates Novartis, Biogen, and Others Over Lucentis Biosimilar

1 year ago talkbio0Tagged Antitrust Probe, Authority, Bioepis, Biogen, Biosimilars, Byooviz, competition, genentech, Italian language, Lucentis, Novartis, Samsung

Italian Competition Authority, Novartis, Biogen, Samsung Bioepis, Genentech, Lucentis, Byooviz, Biosimilar, Antitrust Probe

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

1 year ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Amarin Names New CEO Aaron Berg Following Patrick Holt’s Resignation

1 year ago talkbio0Tagged Aaron Berg, Amarin, CEO, Holt, Leadership, Patrick, resignation, Transition Mutation

Amarin, CEO, Patrick Holt, Aaron Berg, Resignation, Leadership Transition